5 results match your criteria: "Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne[Affiliation]"
The sparing effect of FLASH-RT on synaptic plasticity is maintained in mice with standard fractionation.
Radiother Oncol
September 2023
Laboratory of Radiation Oncology, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Switzerland. Electronic address:
Long-term potentiation (LTP) was used to gauge the impact of conventional and FLASH dose rates on synaptic transmission. Data collected from the hippocampus and medial prefrontal cortex confirmed significant inhibition of LTP after 10 fractions of 3 Gy (30 Gy total) conventional radiotherapy. Remarkably, 10x3Gy FLASH radiotherapy and unirradiated controls were identical and exhibited normal LTP.
View Article and Find Full Text PDFFLASH-RT does not affect chromosome translocations and junction structures beyond that of CONV-RT dose-rates.
bioRxiv
March 2023
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Article Synopsis
- The study investigates the molecular mechanisms behind the improved therapeutic effects of ultra-high dose-rate radiotherapy (FLASH-RT) compared to conventional radiotherapy (CONV-RT), focusing on DNA damage and oxygen levels.
- It examines how FLASH-RT affects genome-wide translocations in different oxygen conditions (normoxic, physioxic, hypoxic) compared to CONV-RT using advanced sequencing techniques.
- Results show that FLASH-RT produces similar levels of chromosomal translocations and repair processes as CONV-RT, regardless of the oxygen tension, challenging the speculation that FLASH-RT leads to lower DNA damage.
CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Clin Cancer Res
July 2021
Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Purpose: The incidence of human papillomavirus-associated head and neck squamous cell carcinoma (HPV-HNSCC) is rising worldwide and although current therapeutic modalities are efficient in the majority of patients, there is a high rate of treatment failures. Thus, novel combination approaches are urgently needed to achieve better disease control in patients with HPV-HNSCC. We investigated the safety and therapeutic efficacy of a novel fibroblast activation protein (FAP)-targeted CD40 agonist (FAP-CD40) in combination with local hypofractionated radiation in a syngeneic HPV-HNSCC model.
View Article and Find Full Text PDFUltra-High-Dose-Rate FLASH Irradiation Limits Reactive Gliosis in the Brain.
Radiat Res
December 2020
Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Encephalic radiation therapy delivered at a conventional dose rate (CONV, 0.1-2.0 Gy/min) elicits a variety of temporally distinct damage signatures that invariably involve persistent indications of neuroinflammation.
View Article and Find Full Text PDFTreatment of a first patient with FLASH-radiotherapy.
Radiother Oncol
October 2019
Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Switzerland; Radiation Oncology Laboratory, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Switzerland.
Background: When compared to conventional radiotherapy (RT) in pre-clinical studies, FLASH-RT was shown to reproducibly spare normal tissues, while preserving the anti-tumor activity. This marked increase of the differential effect between normal tissues and tumors prompted its clinical translation. In this context, we present here the treatment of a first patient with FLASH-RT.
View Article and Find Full Text PDF